Update on the treatment options for multiple sclerosis (Q37729045)

22 August 2017

1 reference

title

Update on the treatment options for multiple sclerosis (English)

1 reference

22 August 2017

0 references

Masaaki Niino

1

1 reference

PubMed ID

20383893

22 August 2017

Hidenao Sasaki

series ordinal

2

1 reference

22 August 2017

1 January 2010

1 reference

Expert Review of Clinical Immunology

22 August 2017

1 reference

22 August 2017

6

1 reference

22 August 2017

1

1 reference

22 August 2017

77-88

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

22 August 2017

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

21 January 2018

1 reference

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

21 January 2018

1 reference

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study

21 January 2018

1 reference

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

21 January 2018

1 reference

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis

21 January 2018

1 reference

Immunosuppression in clinical practice: approaches to individualized therapy

21 January 2018

1 reference

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.

21 January 2018

1 reference

Monoclonal antibodies in the therapy of multiple sclerosis: an overview

21 January 2018

1 reference

Getting specific: monoclonal antibodies in multiple sclerosis.

21 January 2018

1 reference

Immune surveillance in multiple sclerosis patients treated with natalizumab.

21 January 2018

1 reference

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions

21 January 2018

1 reference

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

21 January 2018

1 reference

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature.

21 January 2018

1 reference

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study

21 January 2018

1 reference

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

21 January 2018

1 reference

Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study

21 January 2018

1 reference

Regulation of gene expression associated with acute experimental autoimmune encephalomyelitis by Lovastatin

21 January 2018

1 reference

HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

21 January 2018

1 reference

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

21 January 2018

1 reference

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.

21 January 2018

1 reference

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

21 January 2018

1 reference

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

21 January 2018

1 reference

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

21 January 2018

1 reference

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice

21 January 2018

1 reference

Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial

21 January 2018

1 reference

Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis

21 January 2018

1 reference

Combination therapy in multiple sclerosis.

21 January 2018

1 reference

A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta

21 January 2018

1 reference

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.

21 January 2018

1 reference

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

21 January 2018

1 reference

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

Interferon beta in relapsing–remitting multiple sclerosis

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

Primary progressive multiple sclerosis : current and future treatment options

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ECI.09.75

1 reference

22 August 2017

1 reference

PubMed ID

20383893